Omori K, Inagaki C, Sasa M
Department of Pharmacology, Kansai Medical University, Osaka, Japan.
Nihon Yakurigaku Zasshi. 1999 Sep;114(3):161-8. doi: 10.1254/fpj.114.161.
For the development of new drugs for hitherto untreatable epilepsy, it is necessary to clarify the basic pathophysiology involved in such epileptic seizures and find the target site. This review focused on molecular events related to the expression and expansion of the epileptic focus which are the target of novel antiepileptics. Immediate early genes such as c-fos followed by expression of nerve growth factor (NGF) and brain-derived neurotrophic factor (BDNF) have been evidenced as initial important phenomena in the cascade of molecular systems that develop and complement the transient neuronal excitation to long-term neuronal plasticity. Non-receptor type tyrosine kinase Fyn in the Src family has been suggested to promote kindling development via tyrosine phosphorylation of the NMDA-receptor subunit, NR2B. The cause of abnormality in the inhibitory system is induced by lowering of glutamate-dependent GABA release in the epileptic focus within the hippocampus in human temporal epilepsy. This is probably attributed to a decrease in GABA transporters. Regarding abnormality of the excitatory system, there is an increase in glutamate release prior to convulsive seizures, an enhancement of NMDA receptor responsiveness and high levels of AMPA receptors related to convulsion after completion of kindling. In gene analysis of human familiar epilepsy, abnormalities and point mutations have recently been found in the following genes: KCNQ 2 and KCNQ3, coding for K+ channels; CHRNA4 of the nicotinic receptor subunit alpha 4; and the cystatin B gene. In epilepsy model mice, EL mice with several gene mutations known to be involved in the seizures, the El-1 gene contains an abnormality of the ceruloplasmin gene. SER (spontaneously epileptic rat: zi/zi, tm/tm), a double mutant, manifests a deletion of the region containing the aspartoacylase gene related to the tm gene. Since an increase in N-acetyl-L-aspartate (NAA) is observed in the SER brain, NAA may serve to evoke seizures.
对于开发用于治疗迄今无法治愈的癫痫的新药而言,有必要阐明此类癫痫发作所涉及的基本病理生理学,并找到靶点。本综述聚焦于与癫痫病灶的表达和扩展相关的分子事件,这些事件是新型抗癫痫药物的作用靶点。诸如c-fos等立即早期基因,随后神经生长因子(NGF)和脑源性神经营养因子(BDNF)的表达,已被证明是分子系统级联反应中的初始重要现象,该级联反应将短暂的神经元兴奋发展并补充为长期的神经元可塑性。Src家族中的非受体型酪氨酸激酶Fyn已被认为可通过NMDA受体亚基NR2B的酪氨酸磷酸化促进点燃发展。抑制系统异常的原因是人类颞叶癫痫海马内癫痫病灶中谷氨酸依赖性GABA释放减少所致。这可能归因于GABA转运体的减少。关于兴奋系统的异常,惊厥发作前谷氨酸释放增加,NMDA受体反应性增强,点燃完成后与惊厥相关的AMPA受体水平升高。在人类家族性癫痫的基因分析中,最近在以下基因中发现了异常和点突变:编码K+通道的KCNQ 2和KCNQ3;烟碱样受体亚基α 4的CHRNA4;以及胱抑素B基因。在癫痫模型小鼠中,具有几种已知与癫痫发作有关的基因突变的EL小鼠,El-1基因包含铜蓝蛋白基因的异常。双突变体SER(自发性癫痫大鼠:zi/zi,tm/tm)表现出与tm基因相关的包含天冬氨酸酰基转移酶基因的区域缺失。由于在SER脑中观察到N-乙酰-L-天冬氨酸(NAA)增加,NAA可能引发癫痫发作。